Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Toremifene citrate
Drug ID BADD_D02250
Description A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.
Indications and Usage For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
Marketing Status Prescription
ATC Code L02BA02
DrugBank ID DB00539
KEGG ID D00967
MeSH ID D017312
PubChem ID 3005572
TTD Drug ID D04VFJ
NDC Product Code 69539-152; 64980-404; 52483-0060; 54893-0079; 17337-0305; 73309-291; 72205-050; 42747-327
Synonyms Toremifene | Toremifene, (E)-Isomer | Toremifene Citrate | Citrate, Toremifene | Toremifene Citrate (1:1) | Fareston | FC-1157a | FC 1157a | FC1157a
Chemical Information
Molecular Formula C32H36ClNO8
CAS Registry Number 89778-27-8
SMILES CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O) O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inner ear disorder04.04.02.002--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Oestrogenic effect05.05.04.004--Not Available
The 4th Page    First    Pre   4    Total 4 Pages